Flputnam Investment Management Co. Has $3.89 Million Position in Danaher Co. (NYSE:DHR)

Flputnam Investment Management Co. reduced its stake in shares of Danaher Co. (NYSE:DHR) by 8.5% in the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 16,823 shares of the conglomerate’s stock after selling 1,568 shares during the quarter. Flputnam Investment Management Co.’s holdings in Danaher were worth $3,892,000 as of its most recent filing with the SEC.

Several other institutional investors have also made changes to their positions in DHR. Fairfield Bush & CO. lifted its stake in Danaher by 10.9% in the first quarter. Fairfield Bush & CO. now owns 4,840 shares of the conglomerate’s stock valued at $1,420,000 after acquiring an additional 475 shares during the last quarter. Zions Bancorporation N.A. lifted its stake in Danaher by 19.3% in the first quarter. Zions Bancorporation N.A. now owns 2,468 shares of the conglomerate’s stock valued at $724,000 after acquiring an additional 400 shares during the last quarter. Covestor Ltd lifted its stake in Danaher by 76.8% in the first quarter. Covestor Ltd now owns 495 shares of the conglomerate’s stock valued at $145,000 after acquiring an additional 215 shares during the last quarter. NewEdge Advisors LLC lifted its stake in Danaher by 14.1% in the first quarter. NewEdge Advisors LLC now owns 31,530 shares of the conglomerate’s stock valued at $9,248,000 after acquiring an additional 3,897 shares during the last quarter. Finally, Bridgewater Associates LP raised its position in shares of Danaher by 135.9% in the first quarter. Bridgewater Associates LP now owns 35,270 shares of the conglomerate’s stock valued at $10,346,000 after purchasing an additional 20,320 shares during the period. 79.05% of the stock is currently owned by institutional investors and hedge funds.

Insider Transactions at Danaher

In other news, SVP Georgeann Couchara sold 2,622 shares of the business’s stock in a transaction on Tuesday, February 13th. The shares were sold at an average price of $242.67, for a total value of $636,280.74. Following the sale, the senior vice president now owns 4,244 shares of the company’s stock, valued at $1,029,891.48. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. In related news, SVP Georgeann Couchara sold 2,622 shares of the business’s stock in a transaction on Tuesday, February 13th. The shares were sold at an average price of $242.67, for a total transaction of $636,280.74. Following the transaction, the senior vice president now directly owns 4,244 shares in the company, valued at $1,029,891.48. The sale was disclosed in a filing with the SEC, which is available through this link. Also, SVP Daniel Raskas sold 23,757 shares of the business’s stock in a transaction on Monday, February 26th. The stock was sold at an average price of $252.00, for a total transaction of $5,986,764.00. Following the transaction, the senior vice president now owns 38,102 shares in the company, valued at $9,601,704. The disclosure for this sale can be found here. Insiders have sold a total of 32,957 shares of company stock valued at $8,265,802 over the last 90 days. 10.90% of the stock is owned by corporate insiders.

Analyst Ratings Changes

A number of equities analysts recently issued reports on DHR shares. Raymond James boosted their target price on shares of Danaher from $240.00 to $270.00 and gave the stock an “outperform” rating in a research report on Wednesday, January 31st. Citigroup boosted their price target on shares of Danaher from $255.00 to $280.00 and gave the company a “buy” rating in a report on Wednesday, January 31st. StockNews.com lowered shares of Danaher from a “buy” rating to a “hold” rating in a report on Wednesday, January 31st. Barclays upped their target price on shares of Danaher from $240.00 to $260.00 and gave the stock an “equal weight” rating in a report on Wednesday, April 10th. Finally, HSBC initiated coverage on shares of Danaher in a report on Monday, December 18th. They set a “hold” rating for the company. Seven equities research analysts have rated the stock with a hold rating and nine have issued a buy rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $267.43.

Danaher Trading Up 0.1 %

NYSE DHR traded up $0.16 during trading on Tuesday, reaching $239.82. 404,856 shares of the stock traded hands, compared to its average volume of 2,663,654. The firm has a market cap of $177.60 billion, a price-to-earnings ratio of 37.51, a price-to-earnings-growth ratio of 3.65 and a beta of 0.83. The stock’s 50-day moving average price is $249.58 and its 200 day moving average price is $229.84. The company has a quick ratio of 1.37, a current ratio of 1.68 and a debt-to-equity ratio of 0.31. Danaher Co. has a fifty-two week low of $182.09 and a fifty-two week high of $259.00.

Danaher (NYSE:DHR) last announced its quarterly earnings results on Tuesday, January 30th. The conglomerate reported $2.09 earnings per share for the quarter, beating analysts’ consensus estimates of $1.91 by $0.18. Danaher had a net margin of 17.26% and a return on equity of 12.25%. The firm had revenue of $6.41 billion for the quarter, compared to analyst estimates of $6.10 billion. During the same quarter in the previous year, the firm posted $2.87 earnings per share. The business’s revenue was down 10.2% on a year-over-year basis. Analysts predict that Danaher Co. will post 7.62 EPS for the current year.

Danaher Increases Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, April 26th. Stockholders of record on Thursday, March 28th will be given a $0.27 dividend. This represents a $1.08 dividend on an annualized basis and a dividend yield of 0.45%. The ex-dividend date of this dividend is Wednesday, March 27th. This is a positive change from Danaher’s previous quarterly dividend of $0.24. Danaher’s payout ratio is currently 16.90%.

Danaher Company Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.